At Epiloid, we are dedicated to improving the quality of neurological drug testing. Using 3D human cerebral organoid assays, we evaluate drug efficacy prior to clinical trials in order to reduce the staggering costs, waste, and inaccuracies of animal testing. This technology allows us to assess and record cerebral responses to induced neurological diseases – such as Epilepsy and Parkinson’s – which provides more accurate insight into patient responses during clinical trials.
Housed in Downtown Toronto, Epiloid is at the core of neurological innovation. Visit our website below for more information and sign up for our email updates!